Effects of early parenteral iron combined erythropoietin in preterm infants: A randomized controlled trial.
Study Goal
The researchers aimed to evaluate the effect of early parenteral iron supplementation combined with erythropoietin on preventing anemia in preterm infants, including its impact on breastfeeding outcomes.
Results Summary
The study found no significant differences in breastfeeding cases among the groups. Early parenteral iron supplementation combined with erythropoietin improved reticulocyte percentages, reduced total iron binding capacity, and enhanced hemoglobin and mean cell volume levels at 3 months.
Population
Preterm infants
Effective Dosage
Not specified
Duration
2 weeks of life, with follow-up at corrected ages of 1 and 3 months
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
iron supplementation | increase | percentages of reticulocyte | preterm infants | 2.1±0.4 vs 1.7±0.3 | significantly higher | #1 |
iron supplementation combined erythropoietin | increase | percentages of reticulocyte | preterm infants | 2.5±0.3 vs 1.7±0.3 | significantly higher | #2 |
iron supplementation | decrease | total iron binding capacity | preterm infants | 36.7±4.6 vs 41.6±5.2 | significantly lower | #3 |
iron supplementation combined erythropoietin | decrease | total iron binding capacity | preterm infants | 36.0±4.7 vs 41.6±5.2 | significantly lower | #4 |
iron supplementation | no change | RBC counts | preterm infants | - | no significant differences | #5 |
iron supplementation combined erythropoietin | no change | RBC counts | preterm infants | - | no significant differences | #6 |
iron supplementation | no change | hemoglobin levels | preterm infants | - | no significant differences | #7 |
iron supplementation combined erythropoietin | no change | hemoglobin levels | preterm infants | - | no significant differences | #8 |
iron supplementation | no change | ferritin levels | preterm infants | - | no significant differences | #9 |
iron supplementation combined erythropoietin | no change | ferritin levels | preterm infants | - | no significant differences | #10 |
iron supplementation | no change | malondialdehyde levels | preterm infants | - | no significant differences | #11 |
iron supplementation combined erythropoietin | no change | malondialdehyde levels | preterm infants | - | no significant differences | #12 |
iron supplementation | no change | superoxide dismutase levels | preterm infants | - | no significant differences | #13 |
iron supplementation combined erythropoietin | no change | superoxide dismutase levels | preterm infants | - | no significant differences | #14 |
iron supplementation | no change | RBC | preterm infants | - | did not differ | #15 |
iron supplementation combined erythropoietin | no change | RBC | preterm infants | - | did not differ | #16 |
iron supplementation | no change | Hb | preterm infants | - | did not differ | #17 |
iron supplementation combined erythropoietin | no change | Hb | preterm infants | - | did not differ | #18 |
iron supplementation | no change | MCV | preterm infants | - | did not differ | #19 |
iron supplementation combined erythropoietin | no change | MCV | preterm infants | - | did not differ | #20 |
iron supplementation | no change | body weight | preterm infants | - | did not differ | #21 |
iron supplementation combined erythropoietin | no change | body weight | preterm infants | - | did not differ | #22 |
iron supplementation | no change | body length | preterm infants | - | did not differ | #23 |
iron supplementation combined erythropoietin | no change | body length | preterm infants | - | did not differ | #24 |
iron supplementation | no change | head circumference | preterm infants | - | did not differ | #25 |
iron supplementation combined erythropoietin | no change | head circumference | preterm infants | - | did not differ | #26 |
iron supplementation | increase | Hb levels | preterm infants | 123.7±31.6 vs 114.3±21.3 | improved | #27 |
iron supplementation combined erythropoietin | increase | Hb levels | preterm infants | 125.1±21.2 vs 114.3±21.3 | improved | #28 |
iron supplementation | increase | MCV levels | preterm infants | 78.3±4.7 vs 74.1±3.5 | improved | #29 |
iron supplementation combined erythropoietin | increase | MCV levels | preterm infants | 79.1±5.2 vs 74.1±3.5 | improved | #30 |
iron supplementation | no change | RBC | preterm infants | - | were not different | #31 |
iron supplementation combined erythropoietin | no change | RBC | preterm infants | - | were not different | #32 |
iron supplementation | no change | body weight | preterm infants | - | were not different | #33 |
iron supplementation combined erythropoietin | no change | body weight | preterm infants | - | were not different | #34 |
iron supplementation | no change | body length | preterm infants | - | were not different | #35 |
iron supplementation combined erythropoietin | no change | body length | preterm infants | - | were not different | #36 |
iron supplementation | no change | head circumference | preterm infants | - | were not different | #37 |
iron supplementation combined erythropoietin | no change | head circumference | preterm infants | - | were not different | #38 |
BACKGROUD: The aim of the study was to evaluate the effect of early parenteral iron supplementation combined erythropoietin for prevention of anemia in preterm infants. METHODS: In total, 96 preterm infants were randomly assigned to 3 groups: a control group receiving standard parenteral nutrition (group 1: n = 31), an iron-supplemented group (group 2: IS, n = 33), and an iron-supplemented combined erythropoietin group (group 3: IS+EPO, n = 32). The primary objective was to assess hemoglobin (Hb) levels. The secondary objectives included assessment of red blood cell counts (RBC), mean cell volume (MCV), serum iron, ferritin, percentages of reticulocyte (RET), total iron binding capacity (TIBC) and oxidative stress, which was assessed by measuring plasma levels of malondialdehyde and superoxide dismutase at baseline and at 2 weeks. The blood routine indices including Hb, RBC, MCV, and percentages of RET were measured at corrected age of 1 and 3 months. RESULTS: At 2 weeks of life, the percentages of reticulocyte in group 2 and group 3 were significantly higher than those in group 1 (2.1±0.4, 2.5±0.3, and 1.7±0.3, respectively, P < 0.001, P<0.001), whereas TIBC were significantly lower than those in group 1 (36.7±4.6, 36.0±4.7, and 41.6 ± 5.2 respectively, P = 0.011, P = 0.006). There were no significant differences in RBC counts, the levels of hemoglobin, ferritin, malondialdehyde, and superoxide dismutase among the 3 groups at 2weeks of life. RBC, Hb, MCV, body weight, body length, and head circumference at a corrected age of 1 month did not differ among 3 groups. At corrected age of 3months, more infants in the control group had abnormal Hb and MCV levels (Hb levels: 114.3 ± 21.3, 123.7 ± 31.6, and 125.1 ± 21.2, P = 0.021, P = 0.034, respectively; MCV: 74.1 ± 3.5, 78.3 ± 4.7 and 79.1 ± 5.2, P = 0.017, P = 0.012, respectively), whereas cases of oral iron, cases of breastfeeding, RBC, body weight, body length, and head circumference were not different among 3 groups. CONCLUSION: Early parenteral iron supplementation combined erythropoietin in preterm infants improved the percentages of reticulocyte, decreased total iron binding capacity, and improved the Hb and MCV levels at 3 months of age. Early parenteral iron supplementations with EPO were beneficial for the preterm infants.